Norbert Bischofberger (Kronos)
Kronos seals pact with regulators to hunt AML with previously off-limits biomarker endpoint
As head of R&D at Gilead, Norbert Bischofberger shelved the SYK inhibitor entospletinib after it proved to need too lengthy a development cycle to win …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.